Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02461745 · ClinicalTrials.gov registry record · Phase 4
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
A Phase 4 study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT02461745 is a Phase 4 study that has completed, run by Kaiser Permanente. The registered enrollment target is 200 participants.
The verdict
NCT02461745, a Phase 4 study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasabuvir), with or without RBV (ribavirin).
Interventions
- DRUG ombitasvir, paritaprevir/r, dasabuvir + ribavirin
- DRUG ombitasvir, paritaprevir/r, dasabuvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02461745
The ClinicalTrials.gov registry entry for NCT02461745 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ombitasvir, paritaprevir/r, dasabuvir + ribavirin is the first listed.
NCT02461745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02461745 about?
NCT02461745 is a clinical study titled "Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO". This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvi...
What is the current status of trial NCT02461745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2015-06. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02461745?
The interventions under investigation include: ombitasvir, paritaprevir/r, dasabuvir + ribavirin (DRUG), ombitasvir, paritaprevir/r, dasabuvir (DRUG).
Who is sponsoring clinical trial NCT02461745?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.